IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer

Abstract

Despite a major improvement in the treatment of advanced kidney cancer by the recent introduction of targeted agents such as multi-kinase inhibitors, long-term benefits are still limited and a significant unmet medical need remains for this disease. Cancer immunotherapy has shown its potential by the induction of long-lasting responses in a small subset of patients, however, the unspecific immune interventions with (high dose) cytokines used so far are associated with significant side effects. Specific cancer immunotherapy may circumvent these problems by attacking tumor cells while sparing normal tissue with the use of multi-peptide vaccination being one of the most promising strategies. We here summarize the clinical and translational data from phase I and II trials investigating IMA901. Significant associations of clinical benefit with detectable T cell responses against the IMA901 peptides and encouraging survival data in treated patients has prompted the start of a randomized, controlled phase III trial in 1st line advanced RCC with survival results expected toward the end of 2015. Potential combination strategies with the recently discovered so-called checkpoint inhibitors are also discussed.

Abbreviations

μg

Microgram

5-FU

5 fluorouracil

AE

Adverse event

ccRCC

Clear cell renal cell carcinoma

CTL

Cytotoxic T-lymphocyte

CY

Cyclophosphamide

DC

Dendritic cell

DCR

Disease control rate

ECG

Electrocardiogram

ELISpot

Enzyme-linked immunospot assay

FDA

Food and Drug Administration

HBV

Hepatitis B virus

HLA

Human leukocyte antigen

i.d.

intradermal, intradermally

IFN

Interferon

IL

Interleukin

mg

Milligram

MHC

Major histocompatibility complex

mRNA

Messenger ribonucleic acid

MDSC

Myeloid-derived suppressor cells

MSKCC

Memorial Sloan Kettering Cancer Center

mTOR

Mammalian target of rapamycin

n

Number

NCI-CTC

National Cancer Institute-Common Toxicity Criteria

OS

Overall survival

PD

Progressive disease

PFS

Progression-free survival

PK

Pharmacokinetic

PR

Partial response

RCC

Renal cell carcinoma

RECIST

Response Evaluation Criteria in Solid Tumors

SAE

Serious adverse event

s.c.

subcutaneous, subcutaneously

SD

Stable disease

TKI

Tyrosine-kinase inhibitors

TNF

Tumor necrosis factor

Tregs

Regulatory T-cells

TUMAP

Tumor-associated peptides

VEGF

Vascular endothelial growth factor

Introduction

Renal cell carcinoma (RCC)

Renal cell carcinoma (RCC) is the most common kidney cancer accounting for 85% of all kidney cancers.¹ RCCs arise from the renal tubular epithelium ² and are mostly adenocarcinomas.³ Kidney cancer belongs to the 10 most common cancers and is responsible for 1.9% of all cancers worldwide.⁴ The incidence varies widely with higher rates in US and Europe and lower rates in Asian countries.^5,6 About twice as many men as women are diagnosed with RCC.^4,5,7,8 80% of RCCs are diagnosed in patients aged between 40 and 69 years with an average age in the low 60s.^9,10 Worldwide, the incidence of total kidney cancer and simultaneously RCC has steadily increased over the last 2 decades, while the mortality has decreased. ^5,8,9, ^11-13 This rise in incidence appears to result from an increase in the frequency of risk factors such as obesity and smoking and in the more frequent usage of diagnostic imaging procedures.^11,12,14-16 In the US, an estimated 63,920 people (39,140 male; 24,780 female) will be diagnosed with RCC, and about 13,860 (8,900 male; 4,960 female) will die from this disease during the year 2014.¹⁷ The 5-year overall survival rates for patients diagnosed with localized, regional or distant disease between 1999 and 2005 were 90.4%, 62.3% and 10.4%, respectively.⁸ In Europe, kidney cancer was the 9th most common malignancy in 2008 with 88,400 new cases (56,000 men; 32,400 women) and 39,300 deaths (24,800 men; 14,500 women).¹⁸

RCC is a heterogeneous, malignant disease and has traditionally been classified according to mainly histological features, which are generated through examining excised tumor tissues.¹⁹ Based on the findings of routinely conducted histological assessments, patients are grouped into 5 major histologic subtypes, which differ in prognosis and response to anti-tumor therapy.^20,21 Clear cell renal cell carcinoma (ccRCC) is the most prevalent histologic subtype being assigned to 70–80% of all RCC patients. The prognosis of patients with ccRCCs is less favorable compared with papillary (chromophile) RCCs accounting for 10–15% of RCCs and chromophobe RCCs being responsible for 3–5% of RCC cases.^22,23 Rare histologic RCC subtypes, such as collecting duct carcinomas are aggressive diseases associated with poor outcome.²⁴

Treatment of advanced RCC

Nephrectomy, ideally with curative or at least with debulking intent, is the treatment of choice for advanced and metastatic RCC.²⁵ Additionally, metastasectomy should be considered for patients with solitary lung, bone or brain metastases and a potentially resectable primary tumor as well as for patients with a solitary recurrence after a long disease-free interval.^26,27 Radiotherapy and chemotherapy is barely effective and should be mainly considered as palliative treatment in RCC patients. Unspecific immunotherapy, mostly consisting of interleukin (IL)‑2 and/or interferon (IFN)‑α with or without 5‑fluorouracil (5-FU) has been the only systemic treatment option for many years leading to clinical improvements in a small proportion of patients, however at the cost of substantial toxicities.²⁵ A significant change in standard of care has been introduced with the approval of targeted therapies including tyrosine kinase inhibitors (TKIs) and inhibitors of the mammalian target of rapamycin (mTOR inhibitors). The TKIs sunitinib (Sutent®) and pazopanib (Votrient®) are well established first-line therapies. Other first-line therapy options include the monoclonal antibody bevacizumab (Avastin®) combined with IFN‑α and the mTOR inhibitor temsirolimus (Torisel®), the latter for poor-risk patients. Selected first-line patients may be treated with high dose IL-2 or sorafenib (Nexavar®). Standard second-line therapies include sorafenib (Nexavar®), everolimus (Afinitor®), axitinib (Inlyta®) and IL-2.^28–31 However, despite the significant clinical improvements on the progression of disease seen with these targeted agents, there still remains a significant medical need for additional treatment options as the effect of TKI and mTOR-inhibitors on survival seem to be relatively marginal and almost all of advanced RCC patients still die of their disease. Unspecific immunotherapy with cytokines has shown promise in advanced RCC achieving long-term response and survival in a small fraction of patients albeit with significant side effects. Improved cancer immunotherapy approaches such as (peptide-based) cancer vaccines are therefore of high interest.

Peptide-based cancer vaccines

Active immunotherapy of cancer is based on the premise that a vaccine targeting tumor-associated antigens will raise a cytotoxic immune response to these antigens, destroying malignant cells without harming normal cells. Human leukocyte antigen (HLA) molecules, also known as MHC (major histocompatibility complex) molecules, present peptide fragments derived from internal cellular proteins on the cell surface, thus permitting T cells to discriminate between healthy cells and diseased cells including virus-infected and tumor cells.³² The peptides which are predominantly presented on tumor cells (and not at all or to a far lesser degree on healthy cells) are named TUMAPs (tumor-associated peptides).

HLA molecules occur in many different forms, known as alleles. While hundreds of different alleles exist, some of them are predominantly present in human populations. For example, the allele HLA-A*02 is expressed by 45–50% of the Caucasian population, while the allele HLA-A*24 is expressed by over 60% of the South-East-Asian population. As the interactions between TUMAPs and their corresponding HLA allele are highly specific, only patients expressing the respective HLA allele(s) can benefit from receiving a given TUMAP-based immunotherapy.

A cytotoxic T cell specific for a certain tumor-associated peptide (TUMAP) will recognize a tumor cell through interaction with this HLA molecule-bound TUMAP presented on the cell surface.

There are 2 kinds of TUMAPs:

1. Class I TUMAPs are oligopeptides (8 to 10 amino acids) which activate CD8+ cytotoxic T lymphocytes (CTLs). Activated CTLs have the potential to directly kill tumor cells that present such TUMAPs by releasing cytolytic substances, or by forcing tumor cells into apoptosis.

2. Class II TUMAPs are longer peptides (approximately 15 or more amino acids), which activate CD4+ T-helper cells. Activated T-helper cells support CTLs by locally increasing the concentration of certain cytokines and stimulating the production of antibodies by B cells.

Despite the ability of T cells to detect TUMAPs that are naturally presented by most tumor cells, naturally occurring T cells are not activated (or even silenced by the tumor) and, therefore, do not protect the body against cancer. This requires the help of co-stimulatory molecules. These co-stimulatory molecules are exclusively expressed on professional antigen-presenting cells, e.g. dendritic cells (DCs).

Vaccination with TUMAPs is believed to activate the immune system against cancer in 4 stages (Fig. 1). The underlying activation cascade comprises vaccination, priming, proliferation and elimination as described in detail below.

Figure 1.

Vaccination with several TUMAPs simultaneously triggers a broad immune attack against the tumor.

Vaccination: TUMAPs are dissolved in aqueous buffer and administered intradermally together with adjuvants/immunomodulators, e.g., GM-CSF. GM-CSF creates an inflammatory milieu and helps to recruit DCs to the administration site as well as maturate DCs for full expression of co-stimulatory molecules.³³

Priming: TUMAPs injected into the skin bind to dermal DCs. TUMAPs are loaded onto HLA molecules that are located on the surface of the DCs without any further requirement of processing. DCs then migrate into the lymph nodes, where they encounter and activate (“prime”) naïve T cells specifically recognizing the TUMAPs used in the vaccine.

Proliferation: Once T cells are primed by DCs, their number increases rapidly (clonal proliferation). Soon thereafter, they leave the lymph nodes and begin searching for tumor cells displaying exactly the same TUMAP by which they were activated in the process of priming.

Elimination: Once CTLs recognize a TUMAP on the HLA molecules of tumor cells, they are able to mount a cytolytic/apoptotic attack against the tumor cells.

The priming of CTLs directed against only one specificity, i.e. a single tumor antigen, is normally not sufficient to eradicate all tumor cells. Tumor cells have the ability to mutate more frequently than other cells and are thus able to evade a CTL attack by changing their protein expression pattern and in this way can no longer be recognized by CTLs (so-called “tumor escape”). Vaccination with multiple TUMAPs allows the priming of different T-cells that can act synergistically by simultaneously recognizing a matching number of independently encoded tumor antigens.

IMA901 vaccine

IMA901 is composed of 9 HLA class I-binding tumor-associated peptides (TUMAPs) with the capacity to activate CD8+ CTLs and one HLA class II-binding TUMAP with the capacity to activate CD4+ helper T-cells. Figure 2 describes the process of identifying the HLA class I and II TUMAPs by using an integrated functional genomics approach combining gene expression analysis, mass spectrometry, and T-cell immunology.³⁴ This methodology served as the basis for selection of the TUMAPs included in IMA901. By analyzing tumor samples from more than 30 RCC patients, this selection procedure ensures that the majority of RCC tumors in a patient population are recognized by the induced T cells.

Figure 2.

Selection, Identification and Validation of TUMAPs.

Samples from surgically removed malignant tissue from RCC patients and blood from healthy donors were analyzed as follows:

1. HLA ligands from the malignant material were identified by mass spectrometry.

2. Genes that were over-expressed in the malignant RCC tissue compared with a range of normal organs and tissues were identified using genome-wide messenger ribonucleic acid (mRNA) expression analysis by microarrays.

3. Gene expression data were compared to identify HLA ligands. Peptides that were encoded by selectively expressed or overexpressed genes as detected in step 2 were considered potential candidates for a multi-peptide vaccine.

4. Literature research was conducted with the intention to identify additional evidence for the relevance of the TUMAP candidates.

5. At the mRNA level, the relevance of over-expression was verified by redetection of the selected TUMAPs from step 3 on tumor tissue.

6. Several immunoassays (in vitro T-cell assays) were used to test the reactivity of peripheral T-cells from blood of healthy persons against the TUMAP candidates. It can be speculated, that the IMA901 in vitro immunogenicity data obtained by analyzing PBMCs from HLA-A*02+ healthy individuals as well as from HLA-A*02+ RCC patients would have been similar, as this could be shown for IMA950, a sister product of IMA901 developed by the same technology platform for the treatment of glioblastoma.³⁵

The most relevant results of the multi-step procedure leading to selection of TUMAPs for IMA901 are summarized in Table 1 for each peptide. “X” indicates that a criterion was fulfilled for the respective TUMAP.

Table 1.

Summary of peptide selection

	HLA class I TUMAPs									HLA class II TUMAP
TUMAP selection criteria	IMA-ADF-001	IMA-ADF-002	IMA-APO-001	IMA-CCN-001	IMA-GUC-001	IMA-K67–001	IMA-MET-001	IMA-MUC-001	IMA-RGS-001	IMA-MMP-001
Natural TUMAP presentation on RCC samples
Natural presentation directly shown on RCC tumor samples	X	X	X	—	X	X	X	—	X	X
TUMAP binding to HLA
Demonstrated high-affinity binding to HLA-A*02	X	X	X	X	X	X	X	(X)	—
Predicted promiscuous binding to HLA-DR in >80% of patients1										X
Demonstrated promiscuous binding to class II alleles1										X
mRNA overexpression of TUMAP source protein
Over-expression in RCC samples (% of analyzed RCC samples)2	95	95	100	93	90	85	98	65	80	70
Immunogenicity of TUMAPs
In vitro immunogenicity demonstrated	X	X	X	X	X	X	X	X	X	X
Immunogenicity proven in clinical trials	X	X	X	X	X	X	X	X	X	X
Relevant cancer-associated functions of source proteins
roles in cell cycle progression and tumor cell proliferation				X		X				X
tumor invasion, cell migration, and metastasis					X		X			X
linked to cancer-associated signaling pathways				X	X		X			X
antiapoptotic effects										X
pro-angiogenic effects							X		X
renal cell carcinoma marker	X	X					X			X
expression associated with mutations in the VHL gene	X	X		X
expression correlated with higher tumor stage/grade				X				X	X	X
overexpression linked to decreased survival in RCC							X		X	X

¹Not applicable to short HLA class I TUMAPs.

²Number of samples with expression > mean expression by normal tissues.

Adjuvants/Immunostimulants

TUMAPs are on their own poorly immunogenic unless the presenting cells (i.e., DCs) are further activated to allow for full T cell priming and stimulation. Therefore, the co-administration of immunological adjuvants or immunomodulators is crucial for eliciting a strong and sustainable immune response against the targeted tumor cells.

GM-CSF

GM-CSF is widely used as an adjuvant in clinical vaccination studies with cellular vaccines, proteins, peptides, or antigen-loaded DCs.³⁶ Autologous and allogenic cancer vaccines genetically modified to generate GM-CSF have been successfully applied in man and are in late-stage clinical development.³⁷ With the FDA approval for Sipuleucel-T (Provenge®), an autologous cancer vaccine modified to produce GM-CSF, the first autologous cellular immunotherapy is available.³⁸ A number of clinical trials mostly using melanoma peptides in combination with GM-CSF have been performed. Some of these pilot trials have demonstrated that a high administration frequency of the peptides, particularly within the first 2 weeks induces effective priming of naive T-cells.^39,40 Meta-analysis of published trials suggested, that 40–80 μg GM-CSF applied s.c. or i.d. for 1–5 d at the site of vaccination improves the cellular immune response, while a systemic treatment with ≥ 100 μg does not enhance the efficacy of a peptide vaccine due to expansion of immune-inhibiting myeloid-derived suppressor cells (MDSCs).⁴¹

GM-CSF was therefore chosen as the immunological adjuvant in clinical studies with IMA901. GM-CSF is applied locally (i.d.) in the low-dose range (75 μg per injection).

Cyclophosphamide

Regulatory T-cells (Tregs) represent a T-cell population that functionally suppresses immune responses by having an influence on other immune effector cells.⁴² Results from experiments using mouse tumor models suggest, that Tregs are the main regulators of tumor-directed immunity specifically suppressing cytotoxic effector functions of CTLs.^43,44 Several phenotypically distinct Treg populations have been described: The focus of most intensive recent research are CD4⁺ CD25⁺ Foxp3^high T cells, which also express glucocorticoid-induced tumor necrosis factor (TNF) receptor-related protein at high levels. These Tregs are thought to be key mediators of peripheral immune tolerance. There is evidence from a number of pre-clinical and clinical studies that low-dose cyclophosphamide (CY) administered prior to vaccination is of benefit to cancer patients most likely through inhibition of Tregs and subsequently enhanced immune responses and/or clinical response to vaccination.^45-51 In addition, positive immunomodulatory effects of CY on dendritic cells ^52-55, other antigen presenting cells⁵², tumor infiltrating cells^53,55,56 and MDSCs^52,57,58 have been shown in in vitro experiments as well as in animal models.

The effect of CY on Tregs was investigated in the phase II study with IMA901 in a randomized fashion.

Results and Discussion

Phase I study with IMA901 in advanced RCC

The study IMA901–101 was an open-label, multicenter, first-in-man trial with the primary objective to investigate systemic safety and local tolerability of IMA901 plus GM-CSF in advanced/metastatic RCC patients. Secondary objectives of the trial were immunogenicity and first signs of anti-tumor activity. The study IMA901–101 enrolled 30 patients with stage III/IV RCC regardless of risk categorization, previous treatments and progressing or non-progressing disease. Except for one patient, all had undergone nephrectomy. 47% of all enrolled patients (n=14) had received previous systemic therapies, most frequently consisting of IFN-α and/or IL-2 and often combined with chemotherapy, being most commonly 5-Fluorouracil (5-FU). The remaining 53% of patients (n=16) had received no systemic treatment before the start of vaccination with IMA901 plus GM-CSF.

After positive eligibility screening, patients received up to 8 vaccinations each consisting of 75 μg GM-CSF applied intradermally followed after 15–30 minutes by intradermally applied 4.13 mg IMA901 (413 μg per peptide). In the phase I trial, an additional (non-TUMAP) peptide derived from Hepatitis B virus was added as a marker peptide to better interpret the association of immunological responses and clinical outcome.⁵⁹ All GM-CSF and IMA901 applications were administered in close proximity at the same injection site in order to re-stimulate (boost) T cells at the same draining lymph node. The vaccination schedule applied is outlined in Table 2.

Table 2.

Vaccination schedule in IMA901–101⁵⁹

Vacc	Vacc 1	Vacc 2	Vacc 3	Vacc 4	Vacc 5	Vacc 6	Vacc 7	Vacc 8
Day	1	2	3	8	15	22	36	64
Weeks	1	1	1	2	3	4	6	10
Time window	+/− 0 Days	+/− 0 Days	+/− 0 Days	+/− 1 Days	+/− 2 Days	+/− 2 Days	+/− 2 Days	+/− 2 Days

Safety was assessed according to NCI-CTC criteria, version 3.0 and comprised continuous adverse event (AE) monitoring, assessment of hematology, biochemistry and urinalysis, physical examinations, ECG, vital signs and pregnancy testing at specified time points. Local tolerability was evaluated based on protocol-defined criteria (i.e. rating of injection site related pain, itching, induration, edema and erythema). The immunogenicity of the vaccination therapy was determined by assessing the T-cell response to single TUMAPs contained in IMA901 before, during and after vaccination by applying amplified IFN-γ ELISpot and amplified HLA multimer assays. Tumor response evaluations according to RECIST 1.0 ⁶⁰ were conducted at baseline and during follow up visit taking place about 3 months after study start (2 months of vaccination and 1 month safety follow up) by the local investigator.

All enrolled patients received at least one dose of study medication and were included into the safety population. Two patients were not HLA-A*02 positive and thus, excluded from the efficacy population (n = 28) after the first 2 vaccinations. Twenty-seven patients completed the regular course of the study and received all 8 vaccinations (one patient received only 7 vaccinations). Treatment with IMA901 plus GM-CSF was safe and overall well tolerated. In summary, 21 patients (70%) experienced at least one treatment-emergent adverse event (in total 83 AEs). The most commonly observed AEs independent of relationship were fatigue (16.7%), cough (13.3%), headache (10.0%), pyrexia (10.0%), influenza (10.0%) and anemia (10.0%). The most common AEs considered at least possibly related to study medication were lymphadenitis (6.7%) and injection site pruritus (6.7%). All treatment-emergent AEs with an anticipated relationship to study drug were mild or moderate (maximum severity of NCI-CTC grade 1 or 2) and no patient discontinued study therapy due to AEs. Three SAEs were observed and all resolved and were considered either not related or unlikely related to study drug. One patient was withdrawn from the study after vaccination 7 due to lack of efficacy and died 2 months later due to tumor progression. No indications of autoimmune reactions were observed. Further to AE recording, a more sensitive, protocol-defined scale was used to evaluate local tolerability. Erythema, induration, edema, itching and pain at the injection site were rated 5 minutes and 24 hours post vaccination and at the end-of-study visit as illustrated in Figure 3.⁵⁹

Figure 3.

Local injection site reactions i.e., erythema, induration, edema, itching and pain 5 minutes and 24 hours post vaccination and about 1 month after last vaccination. (Safety population; N = 30).

The most frequently observed local injection site reaction was erythema experienced by all patients. Induration and itching were reported by about 60% of patients. Edema and pain were experienced by 47% and 20% of patients, respectively. Interestingly, 24 hours after vaccination erythema, induration and edema decreased, whereby itching and pain increased. Nearly all reactions had resolved at the last study visit. Most of these injection site reactions were not reported as AEs since investigators considered them as not fulfilling the predefined AE criteria (NCI-CTC).

The T-cell responses to class I TUMAPs contained in IMA901 were evaluable for 27 out of 28 HLA-A*02 positive patients. Overall, IMA901 was able to induce a T-cell response to at least one class I TUMAP in 74% of immune response evaluable patients (n = 20) and 30% of patients (n = 8) responded to 2 or more TUMAPs and were classified as multi-TUMAP responders (19 % and 11% of patients had a vaccine-induced T-cell response to 2 or 3 TUMAPs, respectively). 52% (n = 14) of patients developed a T-cell response to the viral HBV-derived marker peptide.⁵⁹ The onset of immune response appeared after 8 to 15 days of vaccination (after the 3^rd or 4^th vaccination) in about 70% of patients. The peak of T-cell responses could typically be observed after 6 to 8 vaccinations (in week 4 to 10 after start of treatment). More than 50% of responses were still detected 3 months after the first vaccination. Hence, the vaccination schedule used with intense vaccinations at the beginning and longer intervals later on and, the mode and the route of vaccination seemed to be suitable and were therefore maintained in future trials.⁵⁹

Tumor response evaluations could be undertaken in all 28 HLA-A*02 positive patients. One patient (3.6%) achieved a partial response (PR), 11 patients (39.3%) had stable disease (SD) and 16 patients (57.1%) had progressive disease (PD) according to the local investigator. Thus, 12 patients (42.9%) had responding or stabilized disease at the time of the last study visit being collectively termed patients with clinical benefit.⁵⁹ The analysis included 5 patients without measurable disease at baseline. If no new tumor lesions were discovered at the follow-up visit, the patients had been assessed as having stable disease. The tumor response rate achieved was rather modest, however expected, as it seems to reflect the anticipated mode of action of cancer vaccines^61,62. Similar observations were made in other randomized vaccine trials^38,63-66 showing only a moderate improvement in tumor response-dependent clinical trial endpoints such as objective tumor response rate and progression-free survival. Most importantly, clinical benefit was associated with vaccine-induced immune responses as suggested by the cluster of Multi-TUMAP responders (≥ 2 T-cell responses to TUMAPs) on the right hand side of the waterfall plot (Fig. 4).

Figure 4.

Waterfall plot and vaccine-induced T-cell responses as indicated by the TUMAPs named above the bar representing the percentage of change in longest diameter of target lesions. The occurrence of new lesions is outlined and patients without measurable disease according to RECIST at baseline are marked with a shadow around the zero. Patient numbers and the treatment line of the vaccination therapy are illustrated.

Figure 5 depicts, that 75% of multi-TUMAP responders compared to 26% of non-multi-TUMAP (0–1 T cell responses) responders had stable or responding disease at the follow up visit. In other words, patients with a multiple T-cell response were significantly more likely to experience clinical benefit compared with patients with only 0–1 T-cell responses (Chi squared test, p = 0.0187).⁵⁹ In contrast, no association was found between T cell responses to the viral marker peptide HBV-001 and clinical benefit (Chi squared test, p = 0.6617)⁵⁹ suggesting that the observed positive association of clinical outcome with T cell responses against the vaccinated TUMAPs resembles a true therapeutic effect rather than immune responses being just a marker for overall better baseline characteristics, i.e., being a mere prognostic factor. A similar correlation between vaccine-induced immune responses and clinical benefit (responses as well as OS prolongation) was found for other vaccines applied to patients with RCC and other cancers.^67-71

Figure 5.

Association between vaccine-induced T-cell responses and clinical benefit defined as responding or stable disease after 3 months of vaccination (at the follow up visit). The clinical benefit rates were 14%, 33% and 75% for patients with 0, 1 and ≥ 2 TUMAP responses, respectively. 38% of Non-HBV responders and 47% of HBV responders had their disease controlled at the follow up visit.

Interestingly, an inverse association between Multi-TUMAP responders and pre-vaccination Tregs frequencies could be detected. Patients with a multiple IMA901 TUMAP response had significantly lower pre-vaccination Treg frequencies (Fig. 6) (p = 0.018, Two-sided Wilcoxon scores).⁵⁹

Figure 6.

Association between pre-vaccination Treg frequency and number of induced TUMAP responses (n = 26). Lower pre-vaccination frequencies of Treg cells defined as CD4+Foxp3+ cells among CD45+ lymphocytes (y axis) were associated with the induction of multiple IMA901 TUMAP responses (x axis). Every dot represents one patient and horizontal lines illustrate the median Treg frequencies.

Phase II study with IMA901 in advanced RCC

The IMA901–202 phase II study was designed as a multicenter, open-label, randomized study in patients with RCC to investigate the effect of a systemic treatment with IMA901 plus GM-CSF with or without cyclophosphamide (CY) as an additional immunomodulator. The study population consisted of adult HLA-A*02-positive women or men with advanced clear cell RCC classified as having a favorable or intermediate risk according to the 3-score Memorial Sloan Kettering Cancer Center (MSKCC) risk criteria and having experienced disease progression after previous systemic therapy for advanced disease (tyrosine kinase inhibitors [TKIs] or cytokines). Sixty-eight patients were randomized 1:1 to receive a single infusion of low-dose CY (300 mg/m²) 3 d prior to the first vaccination versus no pre-treatment (33 patients did and 35 patients did not receive pre-treatment with CY). Stratification factors included risk group (favorable or intermediate risk based on the MSKCC criteria) and previous therapy, i.e. TKIs or cytokines. 64 patients were included in the pre-defined efficacy analysis (per protocol population). Patients in both randomization arms received up to 17 vaccinations consisting of 75 μg GM-CSF administered i.d. followed after 10 to 30 minutes by i.d. administration of 4.13 mg IMA901. Tumor assessments were performed by either CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST). All images were assessed locally and reviewed centrally by an independent radiologist and oncologist (both blinded for CY pre-treatment). All patients were followed for survival after the final visit. Safety assessments included continuous adverse event (AE) monitoring and physical examinations, vital signs, ECG, assessment of hematology, blood chemistry and urinalysis at scheduled time points.

The primary endpoint of this study was defined as the disease control rate (DCR; percentage of patients with complete or partial response or stable disease according to RECIST) after 26 weeks of treatment. The main secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, immune responses to peptides contained in IMA901 and monitoring of other immune cell populations with a potential influence on T-cell responses such as Tregs.

IMA901/GM-CSF and the single infusion of low-dose CY were safe and overall well tolerated. The most frequently reported AEs independent of relationship were anemia (24%), asthenia (16%), pyrexia (15%), back pain (12%), dyspnea (12%), and fatigue (10%). Most of the AEs which were considered at least possibly related to treatment with IMA901 and/or GM-CSF were injection site reactions with 15 (22%) patients experiencing at least one type of injection site reaction. Except for one patient, local reactions were mild or moderate in severity. Two serious adverse events which were considered related to treatment with IMA901/GM-CSF were reported: one patient experienced a systemic allergic reaction after the twelfth vaccination (caused by CM-CSF as shown in an in vitro basophil degranulation assay) and for another patient a grade 3 localized allergic reaction was reported after the eleventh vaccination, with no similar signs of intolerance after further vaccinations.

Patients randomized to the 2 arms were well balanced with regard to baseline characteristics, risk factors, and pre-treatments. The analysis of the primary efficacy variable showed a DCR of 24.6% (95% CI: 14.5% to 37.3%) at 6 months. For post-cytokine patients (n = 40) DCR at 6 months was 31% compared to 14% in the post-TKI group (n = 24). Progression-free survival was 3.3 months (post-cytokine group 3.4 months, post-TKI group 2 months). As reported for other cancer vaccines objective responses were infrequent, with one complete and 2 partial responses according to investigators’ assessment and one centrally confirmed partial response. Progression-free survival was comparable in both treatment arms (Fig. 7a).

Figure 7.

OS and PFS of patients treated in the phase II study (per protocol population). (a) PFS of patients pre-treated with cyclophosphamide or without such pre-treatment. (b) OS of patients pre-treated with cyclophosphamide or without such pre-treatment. (c) OS of patients evaluable for immune responses in the following groups: immune responders pre-treated with cyclophosphamide, +Cy ≥ 1; patients pre-treated with cyclophosphamide for whom no immune response was observed, +Cy 0; immune responders without cyclophosphamide pre-treatment, −Cy ≥ 1; patients without cyclophosphamide pre-treatment for whom no immune response was observed, −Cy 0. (d) OS of patients for whom no immune response was observed, immune responders to one TUMAP, immune responders to 2 TUMAPs or immune responders to at least 3 TUMAPs.

Patients were followed for survival during the study and every 3 months thereafter via standardized questionnaires including information on subsequent systemic treatments for advanced RCC. A strong trend toward improved survival was observed in patients who received pre-treatment with CY (HR = 0.57; p = 0.09) (Fig. 7b) compared to patients without CY pre-treatment. Survival rates and median survival observed in the IMA901 phase II study appear to be particularly encouraging when compared to data from studies investigating sunitinib and sorafenib in the same patient population. Median survival in the IMA901–202 phase II study was 19.8 months in all second-line patients previously treated with cytokines and had not been reached (> 26 months) at the time of the data cut-off in patients pretreated with CY. This compares favorably to published results in comparable patients with a median OS of 17.8 months for sorafenib ⁷² and 16.4 months for sunitinib. ⁷³Neither a difference in baseline characteristics (all relevant parameters were indeed very comparable between IMA901–202 phase II study and the above cited sunitinib and sorafenib studies) nor post-study treatments (only 31% of patients received further systemic therapy after IMA901 treatment) were able to explain the favorable survival data in the IMA901 phase II trial.

Immunogenicity (as measured in peripheral blood, N = 61) of IMA901 class I peptides was comparable to that observed in the phase I trial (phase II: 64% immune responders, 27% multi-TUMAP responders). Patients pre-treated with or without CY showed comparable immune response rates, indicating that CY did not alter the induction of T cell responses but rather had a positive effect on the functionality of such T cells either directly or by affecting the tumor microenvironment. Immune responders (response to ≥ 1 TUMAP) had a significantly longer survival compared to non-responders (p = 0.048). Furthermore, longer survival was observed with an increasing number of responses (p = 0.023, log-rank test for trend in patients with increasing number of responses) (Fig. 7d), thereby confirming the hypothesis from the phase I trial results that clinical benefit is associated with the breadth of immune responses. The above mentioned survival benefit of CY-treated patients was observed only in the patients with vaccine-induced immune responses (p = 0.040; HR = 0.38), but not in patients lacking a response to TUMAPs (p = 0.870, HR = 0.92) (Fig. 7c).⁵⁹ This suggests that CY acts as an immune modulator and does not have a single agent activity. The immune modulating effect of CY can be best explained by the observed decrease in regulatory T cells (Tregs): the prospectively defined analysis showed an approximately 20% reduction in regulatory T cells within 3 d (p = 0.013) compared to pre-treatment baseline levels.⁵⁹

Conclusions and future prospects

In summary, these 2 studies showed that IMA901 plus GM-CSF without or with CY is a safe, immunogenic and a promising vaccine to be taken forward into late stage clinical development.

Support for the presence of sufficient anti-tumor activity of IMA901 was derived from the finding in the phase I study that multiple TUMAP responses, but not HBV responses were associated with stable or responding disease. Moreover, OS in the phase II study compared favorably to historic controls and was significantly longer in TUMAP responders corresponding to the anticipated mode of action of cancer vaccines. Based on these data, a randomized, open-label phase III trial investigating IMA901 plus GM-CSF in combination with sunitinib compared to sunitinib alone in first-line advanced RCC patients was initiated in 2011. The recruitment has meanwhile been completed and survival data are expected toward the end of 2015.

The percentage of patients with observed responses to multiple peptides was lower than hoped for in both the phase I and II study (16 out of 61 immune-evaluable patients in the phase II study and 8 out of 27 immune-evaluable patients in the phase I study). While responses to multiple peptides have been hypothesized as a biomarker for efficacy, it has also been shown in the phase II trial that in patients pre-treated with cyclophosphamide (CY) the observation of at least one TUMAP immune response was associated with longer survival. In fact, patients in the ongoing phase III study will all be pre-treated with CY. Furthermore, the phase III study also incorporates a secondary endpoint, which investigates overall survival benefit in a predefined subgroup of patients with high levels of the serum markers CCL17 and/or Apolipoprotein A1. Both markers were associated with longer overall survival and higher immune response rates in the phase II study.

Emerging immunotherapy approaches, with the potential to prevent the down-regulation of a tumor-directed immune response by blocking co-inhibitory receptors on immune cells or their soluble or membrane-bound ligands the so called checkpoint inhibitors, are rational candidates for combination with IMA901. Preclinical findings ^74–77 as well as early clinical data in pancreatic, melanoma and prostate cancer ^78–80 suggest synergistic effects between cancer vaccines and immune checkpoint blockade. Nivolumab, a programmed death-1 (PD-1) inhibitor blocking the PD-1 co-inhibitory receptor on activated T-cells is a promising and in RCC well advanced checkpoint inhibitor, currently being investigated in a phase III trial to assess whether it prolongs survival of second- or third-line RCC patients compared with everolimus. In a previous RCC trial, nivolumab achieved a tumor response rate of 29% with mostly durable responses lasting for 24 or more weeks with manageable toxicities.⁸¹ Lambrolizumab, another promising PD-1 inhibitor is currently being tested in first-line advanced RCC patients in a large phase I/II study in combination with pazopanib. A third interesting potential combination partner, MPDL3280A is an antibody targeting PD-L1. MPDL3280A was investigated in advanced RCC in a phase I dose-finding study.⁸² Tumor responses including complete responses and prolonged disease stabilizations were seen across all dose levels. The PFS rate was 50% at 24 weeks. A randomized phase II study is currently ongoing in initially diagnosed, unresectable advanced or metastatic RCC patients comparing monotherapy with MPDL3280A vs. MPDL3280A in combination with avastin or sunitinib. Some other checkpoint inhibitors, such as pidilizumab (PD-1 inhibitor), MAG-271 (B7-H3 inhibitor), BMS-936559 (PD-L1 inhibitor) and MEDI4736 (PD-L1 inhibitor) are in early RCC clinical trials and could also be synergistic combination partners for IMA901. It can be hypothesized that the addition of IMA901, which is able to induce a multi-clonal and tumor-directed T-cell response could increase the clinical benefit observed with checkpoint inhibitors alone, leading to a considerable prolongation of survival ideally in all patients.

Disclosure of Potential Conflicts of Interest

The authors are employees of Immatics biotechnologies GmbH.